Durect Corp DRRX

NAS: DRRX | ISIN: US2666051048   26/04/2024
0,931 USD (+1,68%)
(+1,68%)   26/04/2024

27 maart 2024 · DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update · Persbericht

20 maart 2024 · DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update · Persbericht

4 maart 2024 · DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada · Persbericht

8 februari 2024 · DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference · Persbericht

9 november 2023 · DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update · Persbericht

7 november 2023 · DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality · Persbericht

7 september 2023 · DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis · Persbericht

31 augustus 2023 · DURECT Corporation Announces Presentations in Upcoming Investor Conferences · Persbericht

9 augustus 2023 · DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update · Persbericht

3 augustus 2023 · DURECT Corporation to Announce Second Quarter 2023 Financial Results and Provide a Business Update · Persbericht

20 juli 2023 · DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules · Persbericht

7 juni 2023 · DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis · Persbericht

8 mei 2023 · DURECT Corporation Reports First Quarter 2023 Financial Results and Business Update · Persbericht

2 mei 2023 · DURECT Corporation to Announce First Quarter 2023 Financial Results and Provide Business Update on May 8 · Persbericht

27 april 2023 · DURECT Corporation to Host KOL Event on Alcohol-Associated Hepatitis · Persbericht

26 april 2023 · DURECT Corporation to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference · Persbericht

10 april 2023 · DURECT Announces Peer-Reviewed Article Accepted for Publication with Additional Data from Previously Completed Phase 2a Study of Larsucosterol in Alcohol-Associated Hepatitis · Persbericht

21 maart 2023 · DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board · Persbericht

9 maart 2023 · DURECT Corporation Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference · Persbericht

7 maart 2023 · DURECT Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and AHFIRM Trial Update · Persbericht

Mijn selecties